CorporateWanbury's Q1 PAT up 5.62 times at Rs 9.5 cr
Pharma major, Wanbury"s net profit has grown 5.62 times at Rs 9.48 crore in Q1FY10 as against Rs 1.43 crore in the year-ago period.
- Glenmark recovers partial losses - Suven Life presents Alzheimer's drug data in Austria meet - Sanofi Pasteur buys majority stake in Shantha Bio - Granules Q1 net up 129% at Rs 6 cr - Govt hints nexus between private, state-owned vaccine units - Fakes make up 20-25% of Rs 85,000 cr pharma sales
Its net sales at Rs 83.74 crore in the reporting quarter rose 25.6 per cent as against Rs 66.66 crore in the year-ago period, a press release issued here today said.
EBITDA margin for Q1FY10 was at 19.60 per cent as against 16.40 per cent in Q1FY09.
Wanbury has registered a compounded annual growth rate of 68 per cent over the last 6-years and has a strong presence in domestic formulations, active pharmaceutical ingredients and contract research and manufacturing services (CRAMS), the release said.